Virtual Pharma-Payer Negotiations May Require More Persistence in COVID-19 Era
Precision's Andrew Cournoyer discusses our research results on the effects of the shift to virtual negotiations between pharma and payers as a result of the COVID-19 pandemic, and the challenges they face going forward.